Controlling gene expression in mammalian cells using Cas13 technology
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13
This study is exploring new ways to control how genes work in human cells, which could make cell therapies, especially for cancer, safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10887511 on NIH RePORTER |
What this research studies
This research focuses on developing innovative tools to control gene expression in mammalian cells, which is crucial for advancing cell therapies. By utilizing a newly discovered RNA-guided RNA nuclease called Cas13, the project aims to create a more effective and reversible method for modulating the mammalian transcriptome. This approach seeks to overcome the limitations of existing gene editing technologies, allowing for precise control of gene activity in response to various signals. Patients may benefit from improved safety and efficacy in cell therapies, particularly in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing CAR T cell therapy or those with cancers that could benefit from advanced gene modulation techniques.
Not a fit: Patients who do not have cancer or are not candidates for cell therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cell therapies for cancer and other diseases.
How similar studies have performed: Other research has shown promise with similar gene editing technologies, but the specific application of Cas13 for transcriptome engineering is relatively novel.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Wong, Wilson — Boston University (Charles River Campus)
- Study coordinator: Wong, Wilson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.